Melvin P. Weinstein, MD
Professor of Medicine and Pathology & Laboratory Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, NJ USA
Melvin P. Weinstein 先生は、微生物検査の領域で長年にわたって大変多くの業績を残されています。
特に血液培養検査の研究において大変著名な先生ですが、現在はCLSI の薬剤感受性検査小委員会の副議長を務めていらっしゃいます。
M100 S28 の作成にも深く関与されており、S27からのUpdateを直接お聞きできる貴重な機会となります。
皆様、奮ってのご参加お待ちしております。
要旨：
The CLSI Subcommittee on Antimicrobial Susceptibility Testing (AST) addresses new developments and controversies related to AST issues on an ongoing basis. The committee holds 2 face-to-face meetings annually, publishes an annual update (M100), and has multiple working groups that work year round. In 2017 and 2018, there have been multiple developments, and M100-S28, published in January 2018, will document these changes. M100 is available for purchase in print and is free of charge online at www.clsi.org. Highlights for 2017 and 2018 include: (1) new/revised breakpoints (BPs) for dalbavancin, ceftazidime-avibactam, piperacillin-tazobactam (for B. fragilis group), ceftolozane-tazobactam (disk zones only) (2) clarifications for testing/reporting colistin and polymyxin B for P. aeruginosa and A. baumannii, atypical (slow growing) staphylococci, and S. schleiferi and S. pseudintermedius vs. oxacillin (3) expanded definitions and discussion of epidemiologic cutoff values (ECVs) with additions of colistin for Enterobacteriaceae, azithromycin for N. gonorrhoeae, and vancomycin for C. difficile (4) new methods for detecting carbapenemase-producing Enterobacteriaceae (mCIM test) and the inhibitory-enhanced imCIM test that can differentiate serine carbapenemases from metallo-beta-lactamases and (5) re-evaluation of the CarbaNP method which works well for P. aeruginosa but poorly for A. baumannii. CLSI working groups are assessing (1) a standardized method for direct disk diffusion AST from positive blood cultures (2) improved AST methods for colistin (3) possible revisions of daptomycin BP for E. faecium (4) ceftaroline BP for S. aureus (5) fluoroquinolone BPs for Enterobacteriaceae and P. aeruginosa (6) fluoroquinolone BP for Shigella spp. Lastly, the Quality Control (QC) Working Group continues to develop and approve QC ranges for the many new antimicrobial agents in early stages of development. These and other developments will be addressed.